The industry expects this momentum will continue until 2011, but the growth rate will slow to normal levels.
The world’s largest fragrance and spice producer, Givaudan Switzerland, saw sales revenue increase by 10% year-on-year to 3.3 billion Swiss francs (3.3 billion U.S. dollars) in the first nine months of this year. The sharp increase in sales revenue in the first nine months of the year was mainly due to Stimulated by strong growth in demand in developing markets.
International Fragrance Company (IFF) stated that in the third quarter, the company’s net profit increased significantly by 46% year-on-year to US$77 million, and sales revenue increased by 10% year-on-year to US$673 million.
Symrise achieved a net profit increase of 81% year-on-year to reach 127 million euros in the first three quarters of this year, and sales revenue rose 16% year-on-year to 1.2 billion euros.
Ibrutinib is a small molecule drug that binds permanently to a protein, Bruton's tyrosine kinase (BTK) that is important in B cells; the drug is used to treat B cell cancers like mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenstrom's macroglobulinemia, a form of non-Hodgkin's lymphoma.
Ibrutinib is used to treat chronic lymphocytic leukemia, Waldenstrom's macroglobulinemia, and as a second-line treatment for mantle cell lymphoma, and marginal zone lymphoma.
We produce a series of complete intermediates for Ibrutinib, intermediate I (CAS No. 330786-24-8) and intermediate II (CAS No. 143900-44-1) etc.
All of our products are with stable production and strict quality control, making sure your experience with Sunshine Biotech is always enriching, satisfying and fulfilling.
Ibrutinib Intermediates,Cas 330786-24-8,Cas 143900-44-1,High Purity Ibrutinib Intermediates
Nanjing Sunshine Biotech Co., Ltd , https://www.sunshine-bio.com